Pitavastatin Calcium API

Name	Pitavastatin calcium
Chinese name	匹伐他汀钙
Cas Number	147526-32-7
Source	India
Qualifications	USDMF/-/-/-/-

Pitavastatin calcium was jointly developed by Nissan Chemical and Kowa. It was first approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) on July 17, 2003, and then on August 3, 2009 Approved by the US Food and Drug Administration (FDA). Pitavastatin calcium is a HMG-CoA reductase inhibitor, used in adjuvant therapy outside of diet control to reduce patients’ elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and High-density lipoprotein cholesterol in patients with high altitude hyperlipidemia or mixed dyslipidemia. Pitavastatin calcium belongs to the third-generation variety and is an upgraded variety of the second-generation statin drugs simvastatin, fluvastatin, and pravastatin. It is used to treat hypercholesterolemia, familial hypercholesterolemia, and stable spots Lumps and medications that prevent plaques from rupturing. The characteristic of pitavastatin calcium is that its small dose can also reduce cholesterol and regulate blood lipids. Years of clinical evidence has shown that the benefits of statins to the human body far outweigh its potential side effects.

Hot Tags: pitavastatin calcium api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Vardenafil API, Lurasidone Hydrochloride API, Oseltamivir Phosphate API, Ranolazine API, Ulipristal Acetate API, Tavaborol API

• Previous: Methimazole API
• Next: Tiapride API